Which has higher earnings & valuation, QGEN or ONC?

Qiagen has higher earnings, but lower revenue than BeOne Medicines. Qiagen is trading at a lower price-to-earnings ratio than BeOne Medicines, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Qiagen $2.09B 3.88 $424.88M $1.91 20.61 BeOne Medicines $5.74B 5.35 $286.93M $4.47 62.62

Is QGEN or ONC more profitable?

Qiagen has a net margin of 19.16% compared to BeOne Medicines' net margin of 8.94%. Qiagen's return on equity of 14.40% beat BeOne Medicines' return on equity. Company Net Margins Return on Equity Return on Assets Qiagen 19.16% 14.40% 8.40% BeOne Medicines 8.94% 12.06% 6.69%

Does the media favor QGEN or ONC?

In the previous week, BeOne Medicines had 10 more articles in the media than Qiagen. MarketBeat recorded 14 mentions for BeOne Medicines and 4 mentions for Qiagen. BeOne Medicines' average media sentiment score of 0.13 beat Qiagen's score of 0.00 indicating that BeOne Medicines is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Qiagen 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral BeOne Medicines 3 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better earnings and valuation, MRNA or QGEN?

Qiagen has higher revenue and earnings than Moderna. Moderna is trading at a lower price-to-earnings ratio than Qiagen, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Moderna $1.94B 13.73 -$2.82B -$8.15 N/A Qiagen $2.09B 3.88 $424.88M $1.91 20.61

Is MRNA or QGEN more profitable?

Qiagen has a net margin of 19.16% compared to Moderna's net margin of -143.55%. Qiagen's return on equity of 14.40% beat Moderna's return on equity. Company Net Margins Return on Equity Return on Assets Moderna -143.55% -26.64% -19.32% Qiagen 19.16% 14.40% 8.40%

Does the media refer more to MRNA or QGEN?

In the previous week, Moderna had 19 more articles in the media than Qiagen. MarketBeat recorded 23 mentions for Moderna and 4 mentions for Qiagen. Moderna's average media sentiment score of 0.50 beat Qiagen's score of 0.00 indicating that Moderna is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Moderna 9 Very Positive mention(s) 3 Positive mention(s) 9 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Qiagen 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger valuation & earnings, BNTX or QGEN?

Qiagen has lower revenue, but higher earnings than BioNTech. BioNTech is trading at a lower price-to-earnings ratio than Qiagen, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio BioNTech $2.81B 8.22 -$1.29B -$5.88 N/A Qiagen $2.09B 3.88 $424.88M $1.91 20.61

Is BNTX or QGEN more profitable?

Qiagen has a net margin of 19.16% compared to BioNTech's net margin of -44.39%. Qiagen's return on equity of 14.40% beat BioNTech's return on equity. Company Net Margins Return on Equity Return on Assets BioNTech -44.39% -5.30% -4.62% Qiagen 19.16% 14.40% 8.40%

Does the media favor BNTX or QGEN?

In the previous week, Qiagen had 1 more articles in the media than BioNTech. MarketBeat recorded 4 mentions for Qiagen and 3 mentions for BioNTech. BioNTech's average media sentiment score of 1.23 beat Qiagen's score of 0.00 indicating that BioNTech is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioNTech 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Qiagen 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable earnings & valuation, ROIV or QGEN?

Qiagen has higher revenue and earnings than Roivant Sciences. Roivant Sciences is trading at a lower price-to-earnings ratio than Qiagen, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Roivant Sciences $8.26M 2,966.77 -$299.77M -$0.60 N/A Qiagen $2.09B 3.88 $424.88M $1.91 20.61

Is ROIV or QGEN more profitable?

Qiagen has a net margin of 19.16% compared to Roivant Sciences' net margin of -3,629.19%. Qiagen's return on equity of 14.40% beat Roivant Sciences' return on equity. Company Net Margins Return on Equity Return on Assets Roivant Sciences -3,629.19% -20.54% -19.43% Qiagen 19.16% 14.40% 8.40%

Does the media refer more to ROIV or QGEN?

In the previous week, Roivant Sciences had 4 more articles in the media than Qiagen. MarketBeat recorded 8 mentions for Roivant Sciences and 4 mentions for Qiagen. Roivant Sciences' average media sentiment score of 1.12 beat Qiagen's score of 0.00 indicating that Roivant Sciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Roivant Sciences 5 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Qiagen 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger valuation & earnings, INSM or QGEN?

Qiagen has higher revenue and earnings than Insmed. Insmed is trading at a lower price-to-earnings ratio than Qiagen, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Insmed $606.42M 36.95 -$1.28B -$5.75 N/A Qiagen $2.09B 3.88 $424.88M $1.91 20.61

Is INSM or QGEN more profitable?

Qiagen has a net margin of 19.16% compared to Insmed's net margin of -144.44%. Qiagen's return on equity of 14.40% beat Insmed's return on equity. Company Net Margins Return on Equity Return on Assets Insmed -144.44% -130.11% -51.57% Qiagen 19.16% 14.40% 8.40%

Does the media refer more to INSM or QGEN?

In the previous week, Insmed had 13 more articles in the media than Qiagen. MarketBeat recorded 17 mentions for Insmed and 4 mentions for Qiagen. Insmed's average media sentiment score of 0.88 beat Qiagen's score of 0.00 indicating that Insmed is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Insmed 10 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Qiagen 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Qiagen (QGEN) Competitors

$39.36 +0.42 (+1.07%)

Closing price 06/26/2026 03:59 PM Eastern

Extended Trading

$39.00 -0.36 (-0.91%)

As of 06/26/2026 07:57 PM Eastern

Compare

QGEN vs. ONC, MRNA, BNTX, ROIV, and INSM

Should you buy Qiagen stock or one of its competitors? MarketBeat compares Qiagen with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Qiagen include BeOne Medicines (ONC), Moderna (MRNA), BioNTech (BNTX), Roivant Sciences (ROIV), and Insmed (INSM). These companies are all part of the "pharmaceutical products" industry.

How does Qiagen compare to BeOne Medicines?

Qiagen (NYSE:QGEN) and BeOne Medicines (NASDAQ:ONC) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, media sentiment, risk, valuation, earnings and dividends.

Qiagen has higher earnings, but lower revenue than BeOne Medicines. Qiagen is trading at a lower price-to-earnings ratio than BeOne Medicines, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Qiagen	$2.09B	3.88	$424.88M	$1.91	20.61
BeOne Medicines	$5.74B	5.35	$286.93M	$4.47	62.62

Qiagen has a net margin of 19.16% compared to BeOne Medicines' net margin of 8.94%. Qiagen's return on equity of 14.40% beat BeOne Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Qiagen	19.16%	14.40%	8.40%
BeOne Medicines	8.94%	12.06%	6.69%

Qiagen has a beta of 0.66, meaning that its stock price is 34% less volatile than the broader market. Comparatively, BeOne Medicines has a beta of 0.49, meaning that its stock price is 51% less volatile than the broader market.

In the previous week, BeOne Medicines had 10 more articles in the media than Qiagen. MarketBeat recorded 14 mentions for BeOne Medicines and 4 mentions for Qiagen. BeOne Medicines' average media sentiment score of 0.13 beat Qiagen's score of 0.00 indicating that BeOne Medicines is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Qiagen	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
BeOne Medicines	3 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Qiagen currently has a consensus price target of $43.15, indicating a potential upside of 9.62%. BeOne Medicines has a consensus price target of $390.00, indicating a potential upside of 39.34%. Given BeOne Medicines' stronger consensus rating and higher possible upside, analysts plainly believe BeOne Medicines is more favorable than Qiagen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Qiagen	1 Sell rating(s)	7 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.38
BeOne Medicines	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	2.93

70.0% of Qiagen shares are held by institutional investors. Comparatively, 48.5% of BeOne Medicines shares are held by institutional investors. 9.0% of Qiagen shares are held by insiders. Comparatively, 6.2% of BeOne Medicines shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

BeOne Medicines beats Qiagen on 10 of the 17 factors compared between the two stocks.

How does Qiagen compare to Moderna?

Moderna (NASDAQ:MRNA) and Qiagen (NYSE:QGEN) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, dividends, media sentiment, earnings and risk.

Moderna currently has a consensus target price of $37.13, suggesting a potential downside of 44.80%. Qiagen has a consensus target price of $43.15, suggesting a potential upside of 9.62%. Given Qiagen's stronger consensus rating and higher probable upside, analysts clearly believe Qiagen is more favorable than Moderna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Moderna	5 Sell rating(s)	11 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.83
Qiagen	1 Sell rating(s)	7 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.38

75.3% of Moderna shares are owned by institutional investors. Comparatively, 70.0% of Qiagen shares are owned by institutional investors. 10.8% of Moderna shares are owned by insiders. Comparatively, 9.0% of Qiagen shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Qiagen has a net margin of 19.16% compared to Moderna's net margin of -143.55%. Qiagen's return on equity of 14.40% beat Moderna's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Moderna	-143.55%	-26.64%	-19.32%
Qiagen	19.16%	14.40%	8.40%

Moderna has a beta of 1.05, suggesting that its share price is 5% more volatile than the broader market. Comparatively, Qiagen has a beta of 0.66, suggesting that its share price is 34% less volatile than the broader market.

In the previous week, Moderna had 19 more articles in the media than Qiagen. MarketBeat recorded 23 mentions for Moderna and 4 mentions for Qiagen. Moderna's average media sentiment score of 0.50 beat Qiagen's score of 0.00 indicating that Moderna is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Moderna	9 Very Positive mention(s)	3 Positive mention(s)	9 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Qiagen	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Qiagen has higher revenue and earnings than Moderna. Moderna is trading at a lower price-to-earnings ratio than Qiagen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Moderna	$1.94B	13.73	-$2.82B	-$8.15	N/A
Qiagen	$2.09B	3.88	$424.88M	$1.91	20.61

Summary

Qiagen beats Moderna on 11 of the 17 factors compared between the two stocks.

How does Qiagen compare to BioNTech?

BioNTech (NASDAQ:BNTX) and Qiagen (NYSE:QGEN) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, valuation, risk, media sentiment, dividends and analyst recommendations.

Qiagen has a net margin of 19.16% compared to BioNTech's net margin of -44.39%. Qiagen's return on equity of 14.40% beat BioNTech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioNTech	-44.39%	-5.30%	-4.62%
Qiagen	19.16%	14.40%	8.40%

BioNTech pays an annual dividend of $1.53 per share and has a dividend yield of 1.7%. Qiagen pays an annual dividend of $0.26 per share and has a dividend yield of 0.7%. BioNTech pays out -26.0% of its earnings in the form of a dividend. Qiagen pays out 13.6% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. BioNTech is clearly the better dividend stock, given its higher yield and lower payout ratio.

In the previous week, Qiagen had 1 more articles in the media than BioNTech. MarketBeat recorded 4 mentions for Qiagen and 3 mentions for BioNTech. BioNTech's average media sentiment score of 1.23 beat Qiagen's score of 0.00 indicating that BioNTech is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioNTech	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Qiagen	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

BioNTech has a beta of 1.32, indicating that its stock price is 32% more volatile than the broader market. Comparatively, Qiagen has a beta of 0.66, indicating that its stock price is 34% less volatile than the broader market.

BioNTech presently has a consensus price target of $129.56, indicating a potential upside of 42.03%. Qiagen has a consensus price target of $43.15, indicating a potential upside of 9.62%. Given BioNTech's stronger consensus rating and higher probable upside, research analysts clearly believe BioNTech is more favorable than Qiagen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioNTech	1 Sell rating(s)	4 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.74
Qiagen	1 Sell rating(s)	7 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.38

15.5% of BioNTech shares are held by institutional investors. Comparatively, 70.0% of Qiagen shares are held by institutional investors. 19.2% of BioNTech shares are held by insiders. Comparatively, 9.0% of Qiagen shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Qiagen has lower revenue, but higher earnings than BioNTech. BioNTech is trading at a lower price-to-earnings ratio than Qiagen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioNTech	$2.81B	8.22	-$1.29B	-$5.88	N/A
Qiagen	$2.09B	3.88	$424.88M	$1.91	20.61

Summary

BioNTech beats Qiagen on 10 of the 18 factors compared between the two stocks.

How does Qiagen compare to Roivant Sciences?

Roivant Sciences (NASDAQ:ROIV) and Qiagen (NYSE:QGEN) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, risk, institutional ownership, valuation, analyst recommendations, dividends and media sentiment.

Roivant Sciences has a beta of 1.13, meaning that its share price is 13% more volatile than the broader market. Comparatively, Qiagen has a beta of 0.66, meaning that its share price is 34% less volatile than the broader market.

64.8% of Roivant Sciences shares are held by institutional investors. Comparatively, 70.0% of Qiagen shares are held by institutional investors. 10.8% of Roivant Sciences shares are held by company insiders. Comparatively, 9.0% of Qiagen shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Qiagen has higher revenue and earnings than Roivant Sciences. Roivant Sciences is trading at a lower price-to-earnings ratio than Qiagen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Roivant Sciences	$8.26M	2,966.77	-$299.77M	-$0.60	N/A
Qiagen	$2.09B	3.88	$424.88M	$1.91	20.61

Roivant Sciences presently has a consensus target price of $33.59, suggesting a potential downside of 1.41%. Qiagen has a consensus target price of $43.15, suggesting a potential upside of 9.62%. Given Qiagen's higher probable upside, analysts clearly believe Qiagen is more favorable than Roivant Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Roivant Sciences	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75
Qiagen	1 Sell rating(s)	7 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.38

Qiagen has a net margin of 19.16% compared to Roivant Sciences' net margin of -3,629.19%. Qiagen's return on equity of 14.40% beat Roivant Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Roivant Sciences	-3,629.19%	-20.54%	-19.43%
Qiagen	19.16%	14.40%	8.40%

In the previous week, Roivant Sciences had 4 more articles in the media than Qiagen. MarketBeat recorded 8 mentions for Roivant Sciences and 4 mentions for Qiagen. Roivant Sciences' average media sentiment score of 1.12 beat Qiagen's score of 0.00 indicating that Roivant Sciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Roivant Sciences	5 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Qiagen	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Qiagen beats Roivant Sciences on 10 of the 17 factors compared between the two stocks.

How does Qiagen compare to Insmed?

Insmed (NASDAQ:INSM) and Qiagen (NYSE:QGEN) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, earnings, risk, dividends, media sentiment, institutional ownership, analyst recommendations and profitability.

Insmed presently has a consensus price target of $211.86, suggesting a potential upside of 104.94%. Qiagen has a consensus price target of $43.15, suggesting a potential upside of 9.62%. Given Insmed's stronger consensus rating and higher possible upside, research analysts plainly believe Insmed is more favorable than Qiagen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Insmed	1 Sell rating(s)	0 Hold rating(s)	23 Buy rating(s)	1 Strong Buy rating(s)	2.96
Qiagen	1 Sell rating(s)	7 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.38

Qiagen has higher revenue and earnings than Insmed. Insmed is trading at a lower price-to-earnings ratio than Qiagen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Insmed	$606.42M	36.95	-$1.28B	-$5.75	N/A
Qiagen	$2.09B	3.88	$424.88M	$1.91	20.61

Insmed has a beta of 0.79, meaning that its stock price is 21% less volatile than the broader market. Comparatively, Qiagen has a beta of 0.66, meaning that its stock price is 34% less volatile than the broader market.

70.0% of Qiagen shares are held by institutional investors. 2.1% of Insmed shares are held by insiders. Comparatively, 9.0% of Qiagen shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Qiagen has a net margin of 19.16% compared to Insmed's net margin of -144.44%. Qiagen's return on equity of 14.40% beat Insmed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Insmed	-144.44%	-130.11%	-51.57%
Qiagen	19.16%	14.40%	8.40%

In the previous week, Insmed had 13 more articles in the media than Qiagen. MarketBeat recorded 17 mentions for Insmed and 4 mentions for Qiagen. Insmed's average media sentiment score of 0.88 beat Qiagen's score of 0.00 indicating that Insmed is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Insmed	10 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Qiagen	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Qiagen beats Insmed on 9 of the 16 factors compared between the two stocks.

Get Qiagen News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding QGEN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

QGEN vs. The Competition

Export

Metric	Qiagen	MED Industry	Medical Sector	NYSE Exchange
Market Cap	$8.02B	$3.55B	$6.70B	$23.23B
Dividend Yield	0.68%	2.25%	2.67%	4.10%
P/E Ratio	20.56	21.56	25.76	31.64
Price / Sales	3.88	337.05	559.40	109.21
Price / Cash	11.44	137.38	46.99	24.58
Price / Book	2.20	8.34	10.77	4.74
Net Income	$424.88M	$23.91M	$3.57B	$1.07B
7 Day Performance	6.37%	3.38%	2.15%	0.99%
1 Month Performance	8.87%	1.51%	1.06%	0.86%
1 Year Performance	-21.72%	65.14%	34.16%	25.19%

Qiagen Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
QGEN Qiagen	3.2314 of 5 stars	$39.36 +1.1%	$43.15 +9.6%	-22.2%	$8.02B	$2.09B	20.56	5,654	Analyst Upgrade
ONC BeOne Medicines	4.7782 of 5 stars	$271.80 +0.6%	$390.00 +43.5%	+10.0%	$29.64B	$5.34B	60.81	12,000	Insider Trade
MRNA Moderna	0.9835 of 5 stars	$59.35 -7.2%	$36.60 -38.3%	+144.3%	$25.38B	$1.94B	N/A	4,700	Trending News Analyst Forecast
BNTX BioNTech	4.2742 of 5 stars	$90.19 -0.8%	$129.56 +43.7%	-14.1%	$22.98B	$3.25B	N/A	7,807	Positive News
ROIV Roivant Sciences	2.04 of 5 stars	$31.25 -0.6%	$33.59 +7.5%	+193.7%	$22.61B	$8.26M	N/A	860	Positive News Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:QGEN) was last updated on 6/27/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Qiagen (QGEN) Competitors

QGEN vs. ONC, MRNA, BNTX, ROIV, and INSM

How does Qiagen compare to BeOne Medicines?

Summary

How does Qiagen compare to Moderna?

Summary

How does Qiagen compare to BioNTech?

Summary

How does Qiagen compare to Roivant Sciences?

Summary

How does Qiagen compare to Insmed?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

QGEN vs. The Competition

Qiagen Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Qiagen (QGEN) Competitors

QGEN vs. ONC, MRNA, BNTX, ROIV, and INSM

How does Qiagen compare to BeOne Medicines?

Which has higher earnings & valuation, QGEN or ONC?

Is QGEN or ONC more profitable?

Which has more risk and volatility, QGEN or ONC?

Does the media favor QGEN or ONC?

Do analysts prefer QGEN or ONC?

Do insiders & institutionals believe in QGEN or ONC?

Summary

How does Qiagen compare to Moderna?

Do analysts prefer MRNA or QGEN?

Do institutionals and insiders have more ownership in MRNA or QGEN?

Is MRNA or QGEN more profitable?

Which has more volatility and risk, MRNA or QGEN?

Does the media refer more to MRNA or QGEN?

Which has better earnings and valuation, MRNA or QGEN?

Summary

How does Qiagen compare to BioNTech?

Is BNTX or QGEN more profitable?

Is BNTX or QGEN a better dividend stock?

Does the media favor BNTX or QGEN?

Which has more risk & volatility, BNTX or QGEN?

Do analysts prefer BNTX or QGEN?

Do insiders and institutionals believe in BNTX or QGEN?

Which has stronger valuation & earnings, BNTX or QGEN?

Summary

How does Qiagen compare to Roivant Sciences?

Which has more risk & volatility, ROIV or QGEN?

Do institutionals and insiders hold more shares of ROIV or QGEN?

Which has preferable earnings & valuation, ROIV or QGEN?

Do analysts recommend ROIV or QGEN?

Is ROIV or QGEN more profitable?

Does the media refer more to ROIV or QGEN?

Summary

How does Qiagen compare to Insmed?

Do analysts recommend INSM or QGEN?

Which has stronger valuation & earnings, INSM or QGEN?

Which has more risk and volatility, INSM or QGEN?

Do institutionals & insiders hold more shares of INSM or QGEN?

Is INSM or QGEN more profitable?

Does the media refer more to INSM or QGEN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

QGEN vs. The Competition

Qiagen Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools